Hospital Universitario Puerta de Hierro -ko ikertzaileekin lankidetzan egindako argitalpenak (7)

2024

  1. Improving the Access of Highly Sensitized Patients to Kidney Transplantation From Deceased Donors: The Spanish PATHI Program With Allocation Based on the Virtual Crossmatch

    Transplantation, Vol. 108, Núm. 3, pp. 787-801

2021

  1. An Fc-free EGFR-specific 4-1BB-agonistic trimerbody displays broad antitumor activity in humanized murine cancer models without toxicity

    Clinical Cancer Research, Vol. 27, Núm. 11, pp. 3167-3177

  2. OX40 agonist BMS-986178 alone or in combination with nivolumab and/or ipilimumab in patients with advanced solid tumors

    Clinical Cancer Research, Vol. 27, Núm. 2, pp. 460-472

2019

  1. Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis

    Leukemia, Vol. 33, Núm. 5, pp. 1256-1267

2018

  1. A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity

    Nature Communications, Vol. 9, Núm. 1

2012

  1. Virotherapy, gene transfer and immunostimulatory monoclonal antibodies

    OncoImmunology, Vol. 1, Núm. 8, pp. 1344-1354

2011

  1. New trends in immunotherapy

    Inmunologia